FIELD: medicine.
SUBSTANCE: invention concerns area of medicine and concerns preparations, the antibody-containing person, applied to treatment of microbacterial infections. The essence of the invention includes the preparations containing human antibodies IgG either secretory IgA, or their admixture, specific to antigens Mycobacterium tuberculosis and the vaccine of Calmette and Guerin in concentration from 40 to 160 mg/ml and suitable pharmaceutical medium.
EFFECT: advantage of the invention consists in scope expansion.
5 cl, 2 ex, 3 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| POLYANTIGENIC VACCINE FOR PREVENTING AND ADJUNCTIVE TREATMENT OF TUBERCULOSIS | 2019 |
|
RU2724896C1 |
| RECOMBINANT TUBERCULOUS VACCINE AND ADJUVANT FOR IT | 2017 |
|
RU2665817C1 |
| RECOMBINANT INFLUENZA VIRUS STRAINS EXPRESSING MYCOBACTERIAL PROTECTIVE ESAT-6 ANTIGEN AND USES THEREOF IN TUBERCULOSIS TREATMENT AND PROPHYLAXIS | 2005 |
|
RU2318872C2 |
| ARTIFICIAL MYCOBACTERIAL PARTICLES AND ANTI-TUBERCULOSIS VACCINE COMPOSITION BASED ON THEREOF | 2003 |
|
RU2242245C2 |
| VACCINES OF RECOMBINANT INTRACELLULAR PATHOGENS AND USES THEREOF | 2001 |
|
RU2266132C2 |
| HBHA-DETECTION OF TUBERCULOSIS AND MYCOBACTERIUM TUBERCULOSIS INFECTION | 2005 |
|
RU2426128C2 |
| IMMUNOGENIC COMPOSITION (VERSIONS) BASED ON RECOMBINANT INTRACELLULAR PATHOGEN | 2003 |
|
RU2337707C2 |
| FUSION PROTEIN, DNA, GENETIC CONSTRUCT, RECOMBINANT CELL, FUSION PROTEIN-BASED VACCINE FOR TUBERCULOSIS PREVENTION AND TREATMENT (VERSIONS) | 2015 |
|
RU2615440C2 |
| VACCINE AGAINST TUBERCULOSIS | 2017 |
|
RU2647831C1 |
| MYCOBACTERIUM TUBERCULOSIS VACCINE | 2009 |
|
RU2473365C1 |
